Ebola breakthrough? new trial aims to stop virus after exposure

NCT ID NCT06841614

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving a vaccine plus an antibody drug right after high-risk Ebola contact can prevent the disease better than the vaccine alone. About 160 people who have had close contact with an Ebola patient (like touching body fluids or a dead body) will be randomly assigned to one of two groups. The goal is to see which approach lowers the chance of getting sick.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EBOLA VIRUS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ebola hemorrhagic fever prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Guinea Centre for Research and Training in Infectious Diseases (CERFIG)

    Conakry, Guinea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • National Institute for Biomedical Research (INRB)

    Kinshasa, Democratic Republic of the Congo

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • National Public Health Institute of Liberia

    Monrovia, Liberia

    Contact Email: •••••@•••••

  • University of Sierra Leone College of Medicine and Allied Health Sciences

    Freetown, Sierra Leone

    Contact Phone: •••-•••-•••• Email: •••••@•••••